Tome M B, Isaac M T
Department of Psychological Medicine, Guy's Campus, London, UK.
Int Clin Psychopharmacol. 1998 Jul;13(4):169-74. doi: 10.1097/00004850-199807000-00003.
The objective of our study was an assessment of outcome in a 1 year 'real world', prospective follow-up study of patients who were treated with paroxetine 20 mg plus pindolol 7.5 mg or paroxetine 20 mg plus placebo for 6 weeks. Eighty patients recruited to a double-blind placebo-controlled randomized 6 weeks study of paroxetine and pindolol were followed up for 6 months and interviewed after 1 year. A Kaplan-Meier survival analysis of the patients who relapsed having taken paroxetine and pindolol, compared with those who relapsed having taken paroxetine and placebo, shows that the pindolol group had a better clinical outcome. After 1 year patients who had responded to medication by 2 weeks had done better than the rest and they had been more compliant with medication for 6 months. There are indications that the earlier a patient responds to medication, the better the long-term outcome.
我们研究的目的是对接受20毫克帕罗西汀加7.5毫克吲哚洛尔或20毫克帕罗西汀加安慰剂治疗6周的患者进行为期1年的“真实世界”前瞻性随访研究，评估其治疗结果。80名被招募参加帕罗西汀和吲哚洛尔双盲安慰剂对照随机6周研究的患者接受了6个月的随访，并在1年后接受了访谈。对服用帕罗西汀和吲哚洛尔后复发的患者与服用帕罗西汀和安慰剂后复发的患者进行Kaplan-Meier生存分析，结果显示吲哚洛尔组的临床结局更好。1年后，在2周内对药物有反应的患者比其他患者表现更好，并且他们在6个月内对药物的依从性更高。有迹象表明，患者对药物反应越早，长期结局越好。
